Please login to the form below

Not currently logged in
Email:
Password:

pegpleranib

This page shows the latest pegpleranib news and features for those working in and with pharma, biotech and healthcare.

Novartis buys two firms in pre-Christmas shopping spree

Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at

Latest news

  • Novartis' AMD drug pegpleranib fails phase III programme Novartis' AMD drug pegpleranib fails phase III programme

    Novartis' AMD drug pegpleranib fails phase III programme. Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit. ... Novartis' hopes of positioning pegpleranib as a duo alongside its big-selling age-related macular

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics